Radnostix, Inc.·Healthcare
Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services in the United States and internationally. It operates through five segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. It offers flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot and pen point markers, and various specialty design items. The Cobalt Products segment produces bulk cobalt; fabricates cobalt capsules for radiation therapy and various industrial applications; and recycles expended cobalt sources. The Radiochemical Products segment produces and distributes various isotopically pure radiochemicals and sodium iodide I-131 generic drug product for medical, industrial, and research applications. The Radiological Services segment provides flood source disposal and gemstones processing services. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. It sells its products directly to end users and distributors. International Isotopes Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.
Healthcare
Drug Manufacturers - Specialty & Generic
41
1997-08-14
1.30

IDAHO FALLS, Idaho, April 1, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company"), a leading manufacturer of radioisotope-focused technologies for medical, industrial, and research applications, today announced its fiscal year 2025 financial results and corporate updates. Fiscal 2025 Highlights Total revenue reached $13.07 million, the second-highest annual revenue in Company history, reflecting healthy demand across core segments despite targeted supply chain challenges.

International Isotopes Inc. (OTCMKTS:INIS - Get Free Report)'s share price passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $0.07 and traded as low as $0.0690. International Isotopes shares last traded at $0.07, with a volume of 101,261 shares trading hands.

International Isotopes Inc. (OTCMKTS:INIS - Get Free Report)'s stock price passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $0.07 and traded as high as $0.0990. International Isotopes shares last traded at $0.0840, with a volume of 98,662 shares trading hands. International Isotopes Stock Performance

International Isotopes Inc. (OTCMKTS:INIS - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $0.07 and traded as low as $0.07. International Isotopes shares last traded at $0.07, with a volume of 5,000 shares. International Isotopes